John McNeil

1 month ago | nature.com | Magdalena Sevilla-Gonzalez |Elizabeth Litkowski |Hyunkyung Kim |Ching-Ti Liu |Chenglong Yu |John McNeil | +12 more

AbstractElevated fasting insulin levels (FI), indicative of altered insulin secretion and sensitivity, may precede type 2 diabetes (T2D) and cardiovascular disease onset. In this study, we group FI-associated genetic variants based on their genetic and phenotypic similarities and identify seven clusters with distinct mechanisms contributing to elevated FI levels.

Jul 22, 2024 | jcvaonline.com | Va Usa |Ok Usa |John McNeil |John Mcneil

Key Wordsalpha-galalpha-gal syndrometicktick biteheparinheparin allergycardiopulmonary bypassbioprosthetic valveGet full text accessLog in, subscribe or purchase for full access. References1. Macher, BA ∙ Galili, U. The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: A carbohydrate of unique evolution and clinical relevanceBiochim Biophys Acta. 2008; 1780:75-882. Galili, U ∙ Mandrell, RE ∙ Hamadeh, RM ...

Mar 29, 2024 | digitalcommons.library.tmc.edu | John McNeil |John Mcneil |Robyn L. Woods |Mark Nelson |Christopher Reid

BACKGROUND: Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disability-free life in healthy seniors is unclear.

Mar 29, 2024 | digitalcommons.library.tmc.edu | John McNeil |John Mcneil |Mark Nelson |Robyn L. Woods |Jessica E. Lockery

BACKGROUND: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo.

Mar 29, 2024 | digitalcommons.library.tmc.edu | John McNeil |John Mcneil |Rory Wolfe |Robyn L. Woods |Andrew M. Tonkin

BACKGROUND: Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who have an increased risk.